https://www.creative-biolabs.com/bsab/bispecific-ad-fiber-knob-cd40-igg-l-scfv-10530.htm
Recombinant Anti-Ad fiber knob x Anti-CD40 Bispecific Antibody (IgG(L)-scFv) (IGLFV-002) - Creative...
Creative Biolabs can provide Recombinant Anti-Ad fiber knob x Anti-CD40 Bispecific Antibody (IgG(L)-scFv)
bispecific antibodyrecombinantadfiberknob
https://www.preprints.org/manuscript/202605.0364
Bispecific T-Cell Engager Clinical Translation Is Not Predicted by Target Antigen Density Alone: A...
Bispecific T-cell engager (TCE) development continues to attract substantial industrial investment alongside a translation record that remains uneven across...
clinical translationis notby targetbispecificcell
https://dspace.rpi.edu/items/b235db2a-be8f-4dc5-b26f-62f9b8f670e8
Purification of bispecific antibodies by multimodal chromatography and identification of...
IgG-like bispecific antibodies (bsAbs) are an emerging class of biotherapeutic molecules that can simultaneously bind two distinct antigens. This dual...
bispecific antibodiespurificationmultimodalchromatographyidentification
https://jdc.jefferson.edu/abingtonfp/85/
"The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myel" by Razwana Khanam, Omer S....
Multiple myeloma is a heterogeneous clonal malignant plasma cell disorder, which remains incurable despite the therapeutic armamentarium's evolution....
role ofbispecific antibodiesrefractorymultipleomer
https://www.bioworld.com/articles/709075-rakovina-therapeutics-synthesizes-new-bispecific-parp-hdac-inhibitors-for-treating-ewing-sarcoma?v=preview
Rakovina Therapeutics synthesizes new bispecific PARP-HDAC inhibitors for treating Ewing sarcoma |...
Rakovina Therapeutics Inc. has described dual NAD+ ADP-ribosyltransferase (poly(ADP-ribose) polymerase; PARP) and histone deacetylase (HDAC) inhibitors...
hdac inhibitorsewing sarcomarakovinatherapeuticsnew
https://www.irst.emr.it/it/pubblicazioni/bispecific-antibodies-for-the-treatment-of-relapsedrefractory-multiple-myeloma-updates-and-future-perspectives
Bispecific antibodies for the treatment of relapsedrefractory multiple myeloma updates and future...
Frontiers in oncology
bispecific antibodiesfor themultiple myelomatreatmentupdates
https://www.lifesciencesipreview.com/lspn-fall-north-america-2024/watch-what-are-the-latest-challenges-in-patenting-biologics-biosimilars-and-bispecific-antibodies
WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific...
WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?
what arethe latestwatchchallengespatenting
https://www.biospace.com/immunomedics-inc-reports-first-clinical-experience-with-new-generation-of-bispecific-antibody
Immunomedics, Inc. Reports First Clinical Experience With New Generation of Bispecific Antibody -...
clinical experiencenew generationbispecific antibodyimmunomedicsinc
https://healthtree.org/dlbcl/community/articles/ash25-bispecific-antibodies-older-adults-lymphoma
Bispecific Antibodies for Older Lymphoma Patients - HealthTree for B-Cell Lymphoma
New studies explored safer first treatments for older adults with B-cell lymphomas, including bispecific antibody combinations.
bispecific antibodiesolderlymphomapatientscell
https://medicaex.com/prnewswire/biotheus-enters-into-strategic-partnership-with-biontech-to-develop-and-commercialize-bispecific-antibody-candidate-targeting-pd-l1-and-vegf-in-multiple-solid-tumor-indications/
Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific...
strategic partnershipbiontechdevelopcommercializebispecific
https://ascopost.com/news/september-2021/bispecific-antibody-epcoritamab-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma/
Bispecific Antibody Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - The ASCO...
In a phase I/II study reported in The Lancet, Hutchings et al found that the novel bispecific antibody epcoritamab produced high response rates in patients...
non hodgkin lymphomabispecific antibodyrefractorycellasco
https://ecancer.org/en/video/9692-amg-757-dll3-targeting-half-life-extended-bispecific-t-cell-engager-immuno-oncology-therapy-in-small-cell-lung-cancer
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in...
Dr Luis Paz-Ares speaks to ecancer about the phase 1 study of AMG 75; a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager im
half lifeamgtargetingextendedbispecific
https://www.explorationpub.com/Journals/etat/Article/1002345
Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an...
Gynecological cancer remains one of the leading causes of mortality worldwide. Recent advances in genomic and molecular sequencing have significantly enhanced...
bispecific antibodiesthe treatmentcervical cancerovarianendometrial
https://cancerterminology.com/cancer-drug/autologous-anti-gd2-anti-psma-4scar-expressing-bispecific-t-cells/
autologous anti-GD2/anti-PSMA 4SCAR-expressing bispecific T cells - Cancer Terminology
t cellsautologousantipsmaexpressing
https://pubmed.ncbi.nlm.nih.gov/34358141/
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
Following the clinical success of cancer immunotherapies such as immune checkpoint inhibitors blocking B7/CTLA-4 or PD-1/PD-L1 signaling and ongoing numerous...
bispecific antibodiessmartarsenalcancer
https://virginiacancerspecialists.com/dictionary/bispecific-antibody-4g7xh22/
bispecific antibody 4G7xH22 - Virginia Cancer Specialists
A bispecific antibody containing a 4G7 hybridoma secreting IgG1 antibody specific for B-lymphocytes and a monoclonal antibody targeting Fc gamma
bispecific antibodycancer specialistsvirginia
https://blogs.shu.edu/cancer/tag/bispecific-antibody/
bispecific antibody | Cancer Biology
bispecific antibodycancer biology
https://oncodailyjournal.com/10.69690/odmj-012-0426-7512/
Frailty, infections, and bispecific antibodies in multiple myeloma: redefining supportive care in...
Bispecific Antibodies | IGRT | Immunoglobulin Replacement Treatment - Frailty, infections, and bispecific antibodies in multiple myeloma: redefining
bispecific antibodiesmultiple myelomasupportive carefrailtyinfections
https://www.ophthalmologymanagement.com/news/2026/ollin-biosciences-reports-positive-results-for-vegf-ang2-bispecific-antibody/
Ollin Biosciences Reports Positive Results for VEGF Ang2 Bispecific Antibody | Ophthalmology...
Jan 8, 2026 - Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through...
positive resultsbispecific antibodyollinbiosciencesreports
https://pharmashots.com/tag/bispecific-antibody-drug-conjugate/
bispecific antibody drug conjugate Archives - PharmaShots
Illuminate.Innovate.Inspire
bispecific antibodydrugconjugatearchives
https://jobs.future.ventures/companies/prellis-biologics/jobs/59771343-senior-scientist-bispecific-antibody-purification
Scientist/Senior Scientist - Bispecific Antibody Purification @ Prellis Biologics | Future Ventures...
Search job openings across the Future Ventures network.
bispecific antibodyscientistseniorpurificationbiologics
https://marketintelo.com/report/bispecific-antibody-oncology-therapeutics-market
Bispecific Antibody Oncology Therapeutics Market Research Report 2034
May 17, 2026 - The bispecific antibody oncology therapeutics market was valued at $11.4 billion in 2025 and is projected to reach $75.2 billion by 2034, growing at 23.8% CAGR.
market research reportbispecific antibodyoncologytherapeutics
https://biotech-365.com/calidi-biotherapeutics-to-present-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-in-a-late-breaking-abstract-at-the-2026-aacr-io-conference-2/
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using...
t cell engagersto presentnew approachbiotherapeuticsbispecific
https://menafn.com/1110011295/Cellcentric-Announces-First-Patients-Dosed-With-Inobrodib-In-Combination-With-Bispecific-Antibodies-In-Multiple-Myeloma
Cellcentric Announces First Patients Dosed With Inobrodib In Combination With Bispecific Antibodies...
bispecific antibodiesannouncesfirstpatientscombination
https://dzl.de/publication/10-1038-s41591-026-04238-4/
Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases -...
Autoimmune-mediated connective tissue diseases such as antisynthetase syndrome (ASyS) and systemic sclerosis (SSc) have a high unmet medical need. Here we...
t cell engagersconnective tissue diseasesbispecifictreatmentrefractory
https://pure.prinsesmaximacentrum.nl/en/publications/immunotherapy-in-a-human-ovarian-cancer-xenograft-model-with-two-/
Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies:...
in aovarian cancermonoclonal antibodiesimmunotherapyhuman
https://mediamedic.co/emerging-therapies-in-gastrointestinal-cancers-advances-in-bispecific-antibodies-and-antibody-drug-conjugates/?php%20echo%20wp_logout_url(%20home_url()%20);%20?
Emerging Therapies in Gastrointestinal Cancers: Advances in Bispecific Antibodies and Antibody-Drug...
Feb 11, 2025 - Antibody-Drug Conjugates in GI Cancers ADCs are designed to enhance the precision of chemotherapy by selectively delivering cytotoxic payloads to tumor cells...
emerging therapiesgastrointestinal cancersbispecific antibodiesadvancesantibody
https://agris.fao.org/search/en/providers/122535/records/65df7e900f3e94b9e5d92bea
Influence of bispecific antibodies on the in vitro bactericidal activity of bovine neutrophils...
bispecific antibodieson thein vitroinfluenceactivity
https://www.texasoncology.com/cancer-care/bispecific-therapy
Bispecific Therapy | Texas Oncology
Texas Oncology delivers leading-edge cancer care, tailored to you.
bispecific therapytexasoncology
https://exactitudeconsultancy.com/reports/73117/bispecific-antibodies-market
Bispecific Antibodies Market Analysis and Insights 2023
The Bispecific Antibodies Market Is Set To Grow At An Estimated CAGR Of 7.5% From 2025 To 2034, Rising From $6.5 Billion In 2024 To $13.2 Billion By 2034.
bispecific antibodiesmarket analysisinsights
https://biopharmaapac.com/news/33/1649/harbour-biomed-announces-ind-approval-for-b7h4x4-1bb-bispecific-antibody.html
Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody
Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody
bispecific antibodyharbourbiomedannouncesind
https://aptevotherapeutics.com/
Aptevo Therapeutics | A clinical-stage biotechnology company focused on developing novel bispecific...
biotechnology companytherapeuticsclinicalstagefocused
https://www.addgene.org/browse/article/28244205/
Addgene: SpyMask enables combinatorial assembly of bispecific binders.
addgeneassemblybispecificbinders
https://www.zymeworks.com/publications/zw171-a-differentiated-21-t-cell-engaging-bispecific-antibody-with-antitumor-activity-in-a-range-of-mesothelin-expressing-cancers/
ZW171, a differentiated 2+1 T cell-engaging bispecific antibody with antitumor activity in a range...
Jan 6, 2026 - ZW171, a differentiated 2+1 T cell-engaging bispecific antibody with antitumor activity in a range of mesothelin-expressing cancers
bispecific antibodycellengagingactivityrange
https://www.sungenbiomed.com/
Sungen: Bispecific Antibody, Bispecific Antibody Companies
bispecific antibodycompanies
https://hstalks.com/t/6196/bispecific-and-multispecific-antibodies-in-biother/?biosci
Bispecific and multispecific antibodies in biotherapeutic drug design | HSTalks
drug designbispecificantibodies
https://www.talk.bio/2026/04/novartis-stands-by-5b-pluvicto-goal.html
Novartis Stands by $5B Pluvicto Goal Despite EU Setback and Bispecific Competition
novartisstandspluvictogoaldespite
https://www.fiercebiotech.com/biotech/merck-pays-700m-bispecific-spying-autoimmune-opening-and-chance-challenge-amgen-cancer
Merck pays $700M for bispecific, spying autoimmune opening and chance to challenge Amgen in cancer...
to challengein cancermerckpaysbispecific
https://themmrf.org/hcp_resources/podcast/
Podcast: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care...
bispecific antibodymeeting updatespodcasthorizonsdosing
https://epub.ub.uni-muenchen.de/122507/
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute...
with tbispecific antibodiescombiningvenetoclaxcell
https://biopharmabytes.com/bcma-targeted-bispecific-antibodies-a-topological-journey-into-myelomas-new-frontier/
BCMA-Targeted Bispecific Antibodies: A Topological Journey into Myelomas New Frontier - Biopharma...
Sep 21, 2025 - Learn more about: BCMA-Targeted Bispecific Antibodies: A Topological Journey into Myelomas New Frontier
bispecific antibodiesnew frontierbcmatargetedjourney
https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd30-cd3-bispecific-antibody-gen3017
Definition of anti-CD30/CD3 bispecific antibody GEN3017 - NCI Drug Dictionary - NCI
Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes...
bispecific antibodydrug dictionarydefinitionnci
https://www.bruker.com/pt/news-and-events/webinars/2022/phase-appropriate-lc-ms-strategy.html
Phase Appropriate LC-MS Strategy for the Rapid Characterization of Bispecific Antibodies | Bruker
for thebispecific antibodiesphaseappropriatelc
https://www.pegsummit.com/22/Streams/bispecific-antibodies
Bispecific Antibodies Stream | PEGS Boston Summit May 2-6, 2022
bispecific antibodiesstreampegsbostonsummit